Klesiewicz K, Orczykowska-Kotyna M, Skiba-Kurek I, Empel J, Kania K, Karczewska E
Eur J Clin Microbiol Infect Dis. 2024; 44(2):405-416.
PMID: 39688753
DOI: 10.1007/s10096-024-05018-z.
Spagnuolo R, Scarlata G, Paravati M, Abenavoli L, Luzza F
Antibiotics (Basel). 2024; 13(4).
PMID: 38667033
PMC: 11047737.
DOI: 10.3390/antibiotics13040357.
Hasanuzzaman M, Bang C, Gong E
J Korean Med Sci. 2024; 39(4):e44.
PMID: 38288543
PMC: 10825452.
DOI: 10.3346/jkms.2024.39.e44.
Khangai A, Saruuljavkhlan B, Azzaya D, Gantuya B, Oyuntsetseg K, Akada J
Microorganisms. 2023; 11(12).
PMID: 38137996
PMC: 10745380.
DOI: 10.3390/microorganisms11122852.
Fernandez-Caso B, Miqueleiz A, Alarcon T
Antibiotics (Basel). 2023; 12(7).
PMID: 37508231
PMC: 10376898.
DOI: 10.3390/antibiotics12071135.
Antibiotic resistance in Helicobacter pylori: From potential biomolecular mechanisms to clinical practice.
Lin Y, Shao Y, Yan J, Ye G
J Clin Lab Anal. 2023; 37(7):e24885.
PMID: 37088871
PMC: 10220298.
DOI: 10.1002/jcla.24885.
Clinical Implication of Drug Resistance for Management.
Argueta E, Ho J, Elfanagely Y, DAgata E, Moss S
Antibiotics (Basel). 2022; 11(12).
PMID: 36551341
PMC: 9774604.
DOI: 10.3390/antibiotics11121684.
Rifabutin as salvage therapy for eradication: Cornerstones and novelties.
Borraccino A, Celiberto F, Pricci M, Girardi B, Iannone A, Rendina M
World J Gastroenterol. 2022; 28(45):6356-6362.
PMID: 36533106
PMC: 9753051.
DOI: 10.3748/wjg.v28.i45.6356.
Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen.
Inokuchi K, Mori H, Matsuzaki J, Hirata K, Harada Y, Saito Y
Helicobacter. 2022; 27(4):e12900.
PMID: 35644041
PMC: 9539484.
DOI: 10.1111/hel.12900.
Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Management (Hp-EuReg).
Nyssen O, Vaira D, Saracino I, Fiorini G, Caldas M, Bujanda L
J Clin Med. 2022; 11(6).
PMID: 35329984
PMC: 8949410.
DOI: 10.3390/jcm11061658.
Comments regarding use of rifabutin for eradication.
Graham D
Therap Adv Gastroenterol. 2021; 14:17562848211044064.
PMID: 34646357
PMC: 8504271.
DOI: 10.1177/17562848211044064.
Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications.
Tshibangu-Kabamba E, Yamaoka Y
Nat Rev Gastroenterol Hepatol. 2021; 18(9):613-629.
PMID: 34002081
DOI: 10.1038/s41575-021-00449-x.
Rifabutin for the Treatment of Infection: A Review.
Gisbert J
Pathogens. 2020; 10(1).
PMID: 33379336
PMC: 7823349.
DOI: 10.3390/pathogens10010015.
Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets.
Roszczenko-Jasinska P, Wojtys M, Jagusztyn-Krynicka E
Appl Microbiol Biotechnol. 2020; 104(23):9891-9905.
PMID: 33052519
PMC: 7666284.
DOI: 10.1007/s00253-020-10945-w.
Rifabutin-Containing Triple Therapy (RHB-105) for Eradication of : Randomized ERADICATE Hp Trial.
Kalfus I, Graham D, Riff D, Panas R
Antibiotics (Basel). 2020; 9(10).
PMID: 33050205
PMC: 7600817.
DOI: 10.3390/antibiotics9100685.
Best Eradication Strategy in the Era of Antibiotic Resistance.
Kim S, Chung J
Antibiotics (Basel). 2020; 9(8).
PMID: 32717826
PMC: 7459868.
DOI: 10.3390/antibiotics9080436.
Resistance patterns of refractory infection in a referral center in the Delaware Valley.
Kumar S, Sangitha R, Nachamkin I, Metz D
GastroHep. 2020; 2(1):6-12.
PMID: 32377173
PMC: 7202550.
DOI: 10.1002/ygh2.382.
Inhibition of RNA Polymerase by Rifampicin and Rifamycin-Like Molecules.
Mosaei H, Zenkin N
EcoSal Plus. 2020; 9(1).
PMID: 32342856
PMC: 11168578.
DOI: 10.1128/ecosalplus.ESP-0017-2019.
Broad spectrum resistance in Helicobacter pylori isolated from gastric biopsies of patients with dyspepsia in Cameroon and efflux-mediated multiresistance detection in MDR isolates.
Kouitcheu Mabeku L, Bille B, Tepap Zemnou C, Tali Nguefack L, Leundji H
BMC Infect Dis. 2019; 19(1):880.
PMID: 31640588
PMC: 6806547.
DOI: 10.1186/s12879-019-4536-8.
Molecular characterization and prevalence of antibiotic resistance in isolates in Kuala Lumpur, Malaysia.
Hanafiah A, Binmaeil H, Ali R, Mohamed Rose I, Lopes B
Infect Drug Resist. 2019; 12:3051-3061.
PMID: 31632095
PMC: 6774992.
DOI: 10.2147/IDR.S219069.